Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
68 hedge funds and large institutions have $91.2M invested in Aevi Genomic Medicine Inc in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 7 closing their positions.
115% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $94.1M → $91.2M (-$2.95M)
1% less funds holding
Funds holding: 69 → 68 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$1.65M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$649K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$638K |
| 4 |
NCMW
Northern Capital Management (Wisconsin)
Madison,
Wisconsin
|
+$205K |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
+$194K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$4.14M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$855K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$555K |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$444K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$278K |
GNMX Hedge Fund Activity: Q3 2016 in Review
68 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q3 2016, worth a combined $91.2M — down 3.1% from $94.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GNMX and 6 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 28 added.
The largest buyer was Casdin Capital, adding an estimated $1.65M. The largest seller was QVT Financial, cutting an estimated $4.14M.
- 68 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q3 2016, down from 69 in Q2 2016.
- Funds reported $91.2M of Aevi Genomic Medicine Inc stock for Q3 2016, down 3.1% quarter-over-quarter.
- 6 funds opened new Aevi Genomic Medicine Inc positions in Q3 2016 and 7 closed out, a net change of -1 holder.
- The largest Aevi Genomic Medicine Inc buyer in Q3 2016 was Casdin Capital, an estimated $1.65M added.
- The largest Aevi Genomic Medicine Inc seller in Q3 2016 was QVT Financial, an estimated $4.14M sold.
Based on aggregated 13F filings for Q3 2016.